Business Wire

Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement


Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.

This press release features multimedia. View the full release here:

The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed.

“This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Microbiome, Ferring Pharmaceuticals. “This collaboration is a successful example of our strategy to use external innovation to build our pipeline complementary to our in-house research; and we aim to do further collaborations to build a vibrant research community.”

Tomas de Wouters, CEO, PharmaBiome said: “The trust of Ferring in our translational approach is an important validation of our work and a unique opportunity to accelerate the development of our rationally designed consortia with an experienced market leader in the microbiome therapeutic field. We are thrilled about the complementary expertise between our companies and look forward to a fruitful collaboration.

Based on two core technologies, PharmaBiome has developed a unique technology platform to select bacterial strains for the design of bacterial consortia as live biotherapeutic products with defined activities - the NicheMap™ and a co-cultivation approach that enables fast and scalable production. PharmaBiome’s programmes aim at a next generation of products that are independent of donor material and deliver exactly the consortium of bacterial strains with the desired activity and therapeutic effect (“defined consortia”).

Ferring is the first company to successfully bring forward a first-in-class FDA approved live microbiome-based therapy to US patients. In addition, Ferring has the proven scale and ability to drive forward clinical trials and manufacture microbiome-based products in what is a pioneering field and has a long heritage within gastroenterology.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries.

Learn more at, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X (Twitter).

About PharmaBiome
PharmaBiome is a biotech company developing therapeutic consortia using gut bacteria for targeted modification of microbiome composition and activity. PharmaBiome’s drug-development platform includes an in vitro culture based technology enabling the quantitative understanding of the link between microbiome composition and activity, the NicheMap™.

Discover more about PharmaBiome:

To view this piece of content from, please give your consent at the top of this page.

Contact information

Matthew Worrall
Director, Corporate Communications and Public Affairs, Ferring
+447442 271811

Tomas de Wouters
CEO, PharmaBiome
+41 44 552 03 04

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Publishes 2023 Annual Report29.2.2024 20:05:00 CET | Press release

SES S.A. has today published its 2023 Annual Report, following the announcement of the company’s full year financial results for the 12 months ended 31 December 2023. Follow us on: LinkedIn | YouTube | Twitter | Facebook | Instagram Read our Blogs > Visit the Media Gallery > About SES SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a leader in global content connectivity solutions, SES owns and operates the world’s only geosynchronous orbit and medium earth orbit (GEO-MEO) constellation of satellites with the unique combination of global coverage and high performance. By leveraging its vast and intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivi

Sebia Receives U.S. FDA Clearance for the FLC Kappa & Lambda Assays29.2.2024 19:30:00 CET | Press release

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the FLC Kappa & Lambda assays. These are the first EIA tests receiving 510(k) from the FDA for the quantitative detection of both kappa and lambda free light chains in human serum specimens, intended for both aid of diagnosis and monitoring of Multiple Myeloma and Immunoglobulin Light-Chain (AL-) amyloidosis. Clinical evaluation of Sebia FLC kappa and FLC lambda assay has shown comparable clinical sensitivity with the Freelite assay (96.6% on 177 samples from patients diagnosed with MM) and improved clinical specificity (85.1% on 189 non-myeloma/non-amyloidosis subjects with various clinical conditions). These excellent performances have been notably highlighted in the Willrich et al publication releas

New PICO ® Nexμs ™ Jetting System Connects Fluid Dispensing to Industry 4.0 Efficiency29.2.2024 16:11:00 CET | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces the PICO Nexμs Jetting System to revolutionize jet dispensing efficiency. This press release features multimedia. View the full release here: Small form factor makes it easy to mount multiple controllers on a DIN rail (Photo: Business Wire) For most automated production machines, standard jetting controllers are panel-mounted away from the point of dispense, making adjustment and monitoring of the dispensing parameters inconvenient to the user. The PICO Nexμs jetting controller eliminates this hassle. Its compact, 24V DIN-rail construction makes it easy to mount inside an existing machine cabinet, saving valuable space near the automated machine. It is especially well suited in multi-valve installations where machine real estate is limited. PICO Nexμs controllers use standard Industrial Ethernet protocols such as

Nippon Shokubai’s Newly Developed Material Contributed the Successful Demonstration of Groundbreaking Renewable Seawater Desalination Plant in Hawaii29.2.2024 16:00:00 CET | Press release

NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023. This press release features multimedia. View the full release here: Figure 1 Comparison between RO system and FO system (Graphic: Business Wire) In recent years, water shortage ha

CORRECTING and REPLACING, H2SITE Has Commissioned a Membrane Separator Capable of Extracting 5 to 20% Hydrogen Blends at +99% Purity From the Gas Distribution Network29.2.2024 15:55:00 CET | Press release

Fourth paragraph should read: "The palladium membrane separators technology employed by H2SITE enables us to produce high-purity hydrogen suitable for fuel cell applications from blends with very low hydrogen concentrations," according to Andrés Galnares, CEO of H2SITE. "We have achieved the separation of over 97% of hydrogen at very high purity in the original gas stream while ensuring that the natural gas we deliver complies with the specifications of existing users." This press release features multimedia. View the full release here: The updated release reads: H2SITE HAS COMMISSIONED A MEMBRANE SEPARATOR CAPABLE OF EXTRACTING 5 TO 20% HYDROGEN BLENDS AT +99% PURITY FROM THE GAS DISTRIBUTION NETWORK Located in Zamudio (Bizkaia), the separation unit is installed on a natural gas distribution network and operates with hydrogen concentrations ranging from 5 to 20% It’s the first installation using palladium-alloy membrane separat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye